• Blog
  • Asthma and COPD Drugs Market Growth Analysis

    Asthma and COPD Drugs Market Growth Analysis

    Asthma and COPD Drugs Market  Growth Analysis
    Report code - SR2219 Delivery - 2 Weeks
    Asthma and COPD Drugs Market Size, Share, Trend, Forecast, Competitive Analysis, and Growt See more...

    Market Highlights

    The Asthma and COPD Drugs Market was estimated at US$ 37.9 billion in 2021 and is expected to grow at a CAGR of 5.34% during 2022-2028 to reach US$ ~54.40 billion in 2028.

    Wish to get a free sample? Register Here

    The global market for asthma and COPD medications is expanding due to factors such as the aging population, technological advancements, and increased asthma and COPD prevalence. Globally, COPD is spreading more quickly. According to the World Health Organization's (WHO) 2021 Dataset, with 3.23 million fatalities in 2019, COPD is the third most common risk factor for death worldwide. More than 80% of the fatalities occurred in developing and middle-income countries. Additionally, the global market for asthma and COPD medications is expanding due to the rising prevalence of asthma. One in every thirteen Americans has asthma, according to a report published in June 2019 by the Asthma and Allergy Foundation of America. Additionally, more than 11.4 million asthmatic individuals with suffered at least one attack in 2017.

    Additionally, the global market for medications to treat COPD and asthma is expanding due to the aging population. In 2020, there will be around 727 million individuals worldwide who are 65 or older, according to the World Ageing 2020 forecast. The world's senior population is projected to reach 1.5 billion by 2050. The percentage of individuals 65 and older worldwide increased from 9.3% in 2020 to 16% in 2050. As a result, this aspect is promoting the growth of the global market for asthma and COPD medications.

    Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market:

    • Asthma is a chronic, inflammatory lung condition affecting the airways that is not contagious. Recurrent wheezing, dyspnea, chest tightness, and coughing bouts are brought on by the hyperresponsiveness of the airways. When compared to other obstructive lung illnesses, asthma is fairly treatable. The biggest risk factor for asthma is allergies. Asthma can also be brought on by irritations, exertion, blocks, cold air, animals, and dust.
    • Airflow restriction is a feature of chronic obstructive pulmonary disease (COPD), which is not entirely curable. Emphysema, a complicated lung illness marked by the destruction of the alveoli, and chronic bronchitis, a persistent inflammation of the lower respiratory tract, are both included in COPD. The primary cause of COPD is tobacco usage. Additionally, COPD risk factors include ambient air pollution, occupational exposure, and passive smoking.

    Segments Analysis

    By Drug Class Type

    The market has been segmented into combination drugs, bronchodilators, inhaled corticosteroids (ICs), short acting beta agonists (SABA), long acting beta agonists (LABA), leukotriene antagonists (LTA), anticholinergics, anti-inflammatories, others. In 2021, the market for medications for COPD and asthma was dominated by combination drugs. Over the past ten years, the use of medicine and medication combinations to treat a range of illnesses has significantly expanded. According to multiple research studies, patients with COPD and asthma can now benefit from combination medications.

    In 2021, the market for asthma and COPD medications will grow fastest in the inhaled corticosteroids (ICS) sector. The inhaled corticosteroids (ICS) assist in improving lung function and preventing asthma episodes. They could potentially be used to treat other respiratory conditions, such as COPD. In comparison to other types of medications, inhaled corticosteroids (ICS) are extremely successful in the treatment of asthma.

    By Application Type

    The asthma and COPD drugs market has been divided into asthma and COPD. In 2021, the asthma sector led the market for asthma and COPD medications. Around the world, asthma is regarded as one of the most serious diseases. The World Health Organization (WHO) estimates that in 2019, asthma affected 262 million people, resulting in 46,1000 fatalities. Asthma is the most prevalent chronic illness among kids. Patients with asthma who use inhaled medications and medicines can better control their symptoms and have healthy lives. Because of this, it is anticipated that the market for medications for COPD and asthma would grow.

    The asthma and COPD medicine market's COPD category is expected to increase at the quickest rate through 2021. The Global Burden of Disease Study from the Institute of Health Metrics and Evaluation in 2016 estimates that there are 215 million cases of COPD worldwide. In 2016, the World Health Organization (WHO) estimated that 200 million individuals globally have COPD. The market for asthma and COPD medications is expanding as a result of factors such as increasing air pollution and harmful gas emissions.

    By Distribution Channel Type

    The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

    Regional Analysis

    The asthma and COPD drugs market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America dominated the market for medications for COPD and asthma. The increased incidence of asthma and COPD is the primary driver of the market for asthma and COPD medications in North America. In the United States, adult women are more likely to have asthma than adult men. The Centers for Disease Control predict that roughly 25 million Americans will have asthma by 2020. This translates to about one in every thirteen Americans, with children making up 7% of this group and adults 8%. Around 20 million Americans suffer from asthma. As a result, the region's market for asthma and COPD medications is expanding due to the increase in asthma patients.

    Want to know which region offers the best growth opportunities? Register Here

    Key Players

    The following are the key players in the asthma and COPD drugs market:

    • Abbott
    • Astellas Pharma
    • Cipla Inc.
    • Glenmark Pharmaceuticals
    • Grifols S.A.
    • Hoffmann-La Roche Ltd
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.

    Rising technological and therapeutic developments as well as an increase in product launches by market participants are factors driving the growth of the global market for asthma and COPD medications. For the introduction of new products, certain governmental organizations work with industry participants.

    For example:

    • In July 2020, AstraZeneca published the encouraging phase III ETHOS research results in the New England Journal of Medicine. The rate of mild to severe symptoms in comparison to the dual combination treatment in patients with mild to severe COPD was observed to be reduced by the triple combination drug PT010.
    • In February 2020, the European Medicines Agency approved GlaxoSmithKline PLC's regulatory submission asking for a new indication for Trelegy Ellipta, a once-daily triple therapy for the treatment of adult asthma.
    • The renowned pharmaceutical company AstraZeneca received EU clearance in December 2020 for Trixeo Aerosphere, a supportive therapy for COPD. Both emerging and developed nations are making significant investments in the creation of novel treatments and pharmaceuticals.
    • In August 2018, the European Commission approved Nucala for the diagnosis of pediatric patients with severe eosinophilic asthma. Given that the impact of the condition is greater in children and adults, its approval will help to meet a sizable unmet need among Europeans.

    The overall competitive landscape has been affected due to these mergers and acquisitions. 

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Asthma and COPD Drugs Market 

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and Forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview Research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

    Frequently Asked Questions (FAQs)

    The asthma and COPD drugs market is expected to grow at a CAGR of 5.34% during 2022-2028.

    The asthma and COPD drugs market size is estimated to grow from US$ 37.9 billion in 2022 to US$ ~54.40 billion in 2028.

    The market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America dominated the market for medications for COPD and asthma.

    Abbott, Astellas Pharma, Cipla Inc., Glenmark Pharmaceuticals, Grifols S.A., Hoffmann-La Roche Ltd., Merck & Co. Inc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. are some of the key players in the market.

    The market has been divided into asthma and COPD. In 2021, the asthma sector led the market for asthma and COPD medications. Around the world, asthma is regarded as one of the most serious diseases.

    Rising technological and therapeutic developments as well as an increase in product launches by market participants are factors driving the growth of the global market for asthma and COPD medications.

    The market is studied from 2016-2028.